BiomX (PHGE) Notes Payables (2018 - 2026)
BiomX's (PHGE) quarterly Notes Payables came in at $1.3 million in Q2 2026, little changed quarter-over-quarter from $1.3 million in Q1 2026.
Analysis
BiomX (PHGE) Notes Payables (2018 - 2026) Analysis & Trends
BiomX has disclosed Notes Payables across 3 years of filings, most recently posting $1.3 million for Q2 2026.
- In Q2 2026, Notes Payables changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (changed N/A YoY), while the FY2019 annual figure was $375000.0, up 650.0% from the prior year.
- Notes Payables came in at $1.3 million for Q2 2026 at BiomX, roughly flat from $1.3 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.3 million in Q1 2026 to a low of $1.3 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.59 Bn | 193.60 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.17 Bn | 123.32 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.01 Bn | 55.82 Bn | 1.37 Bn |
| 6 | Moderna | 53.40 Bn | 48.27 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.64 Bn | 30.35 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.66 Bn | 29.66 Bn | 1.16 Mn |
| 10 | BiomX | 17.64 Mn | 17.06 Mn | 97,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Mn |
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2019 | 375,000.00 |
| Dec 31, 2018 | 50,000.00 |
| Jun 30, 2018 | 40,000.00 |